All Brands Owned by Emergent BioSolutions Inc.

Is Emergent BioSolutions publicly traded?

Yes. It trades on the New York Stock Exchange under the ticker EBS. It has no controlling shareholder, with ownership dispersed among institutional and retail investors.

Who owns Emergent BioSolutions?

No single owner controls it. It is a public company whose shares are held primarily by institutional investors, with founder Fuad El-Hibri's influence ended by his 2022 death.

What does Emergent BioSolutions make?

Its two core businesses are naloxone products (Narcan and KLOXXADO nasal sprays for opioid overdose) and medical countermeasures for anthrax, smallpox, botulism, and Ebola sold to governments.

Who founded Emergent BioSolutions?

Fuad El-Hibri founded the company in 1998 as BioPort, built around the anthrax vaccine licensed from a former Michigan state facility, and renamed it Emergent BioSolutions in 2004.

What is Emergent's market position?

It is a niche specialty pharma leader: the branded leader in naloxone and a primary supplier of US biodefense countermeasures, with FY2025 revenue of $742.9 million.

What was Emergent's biggest controversy?

The 2021 COVID-19 vaccine manufacturing failure at its Baltimore plant, which destroyed millions of doses, triggered FDA action and congressional scrutiny, and led to its exit from contract manufacturing.

Does Emergent own Narcan?

Yes. Emergent acquired Narcan through its October 2018 purchase of Adapt Pharma for up to $735 million and markets it as its flagship commercial product.